Rifaximin Alters Intestinal Microbiota and Prevents Progression of Ankylosing Spondylitis in Mice
Recently, accumulating evidence has suggested that gut microbiota may be involved in the occurrence and development of ankylosing spondylitis (AS). It has been suggested that rifaximin have the ability to modulate the gut bacterial communities, prevent inflammatory response, and modulate gut barrier...
Main Authors: | Lianjun Yang, Bin Liu, Junchi Zheng, Jincheng Huang, Qinghao Zhao, Jinshi Liu, Zhihai Su, Min Wang, Zhifei Cui, Tingxuan Wang, Weicong Zhang, Qingchu Li, Hai Lu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-03-01
|
Series: | Frontiers in Cellular and Infection Microbiology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fcimb.2019.00044/full |
Similar Items
-
Anti‐TNF‐α therapy alters the gut microbiota in proteoglycan‐induced ankylosing spondylitis in mice
by: Bin Liu, et al.
Published: (2019-12-01) -
Adalimumab Therapy Restores the Gut Microbiota in Patients With Ankylosing Spondylitis
by: Zena Chen, et al.
Published: (2021-09-01) -
A Possible Role of Intestinal Microbiota in the Pathogenesis of Ankylosing Spondylitis
by: Lianjun Yang, et al.
Published: (2016-12-01) -
Ankylosing Spondylitis
by: Nazanin Ebrahimiadib, et al.
Published: (2021-07-01) -
Prevalence of fibromyalgia in patients with ankylosing spondylitis
by: Aref Hosseinian Amiri, et al.
Published: (2014-01-01)